Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'HER2/NEU-OVEREXPRESSING METASTATIC BREAST' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 79 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Hosch, SB; Braun, S; Pantel, K
      Characterization of disseminated tumor cells

      SEMINARS IN SURGICAL ONCOLOGY
    2. Normanno, N; Bianco, C; De Luca, A; Salomon, DS
      The role of EGF-related peptides in tumor growth

      FRONTIERS IN BIOSCIENCE
    3. Baselga, J
      Is circulating HER-2 more than just a tumor marker?

      CLINICAL CANCER RESEARCH
    4. Kaptain, S; Tan, LK; Chen, BY
      Her-2/neu and breast cancer

      DIAGNOSTIC MOLECULAR PATHOLOGY
    5. Tsongalis, GJ; Ricci, A
      HER2: The Neu prognostic marker for breast cancer

      CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
    6. Piccart, M; Kaufmann, M
      Herceptin: HER2 status - Changing clinical practice - Introduction

      EUROPEAN JOURNAL OF CANCER
    7. Azios, NG; Romero, FJ; Denton, MC; Doherty, JK; Clinton, GM
      Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor

      ONCOGENE
    8. Fountzilas, G; Tsavdaridis, D; Kalogera-Fountzila, A; Christodoulou, C; Timotheadou, E; Kalofonos, C; Kosmidis, P; Adamou, A; Papakostas, P; Gogas, H; Stathopoulos, G; Razis, E; Bafaloukos, D; Skarlos, D
      Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer - A Hellenic Cooperative Oncology Group phase IIstudy

      ANNALS OF ONCOLOGY
    9. Neve, RM; Lane, HA; Hynes, NE
      The role of overexpressed HER2 in transformation

      ANNALS OF ONCOLOGY
    10. Menard, S; Casalini, P; Campiglio, M; Pupa, S; Agresti, R; Tagliabue, E
      HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer

      ANNALS OF ONCOLOGY
    11. Dillman, RO
      Monoclonal antibodies in the treatment of malignancy: Basic concepts and recent developments

      CANCER INVESTIGATION
    12. Colomer, R; Shamon, LA; Tsai, MS; Lupu, R
      Herceptin: From the bench to the clinic

      CANCER INVESTIGATION
    13. Yamauchi, H; Stearns, V; Hayes, DF
      When is a tumor marker ready for prime time? A case study of c-erbB-2 as apredictive factor in breast cancer

      JOURNAL OF CLINICAL ONCOLOGY
    14. Bast, RC; Ravdin, P; Hayes, DF; Bates, S; Fritsche, H; Jessup, JM; Kemeny, N; Locker, GY; Mennel, RG; Somerfield, MR
      2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology

      JOURNAL OF CLINICAL ONCOLOGY
    15. Penichet, ML; Dela Cruz, JS; Challita-Eid, PM; Rosenblatt, JD; Morrison, SL
      A murine B cell lymphoma expressing human HER2/neu undergoes spontaneous tumor regression and elicits antitumor immunity

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    16. Mueller-Holzner, E; Fink, V; Frede, T; Marth, C
      Immunohistochemical determination of HER2 expression in breast cancer fromcore biopsy specimens: a reliable predictor of HEr2 status of the whole tumor

      BREAST CANCER RESEARCH AND TREATMENT
    17. Baselga, J; Albanell, J; Molina, MA; Arribas, J
      Mechanism of action of trastuzumab and scientific update

      SEMINARS IN ONCOLOGY
    18. Yu, DH
      Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers

      SEMINARS IN ONCOLOGY
    19. Burstein, HJ; Bunnell, CA; Winer, EP
      New cytotoxic agents and schedules for advanced breast cancer

      SEMINARS IN ONCOLOGY
    20. Funkhouser, WK; Kaiser-Rogers, K
      Review: Significance of, and optimal screening for, HER-2 gene amplification and protein overexpression in breast carcinoma

      ANNALS OF CLINICAL AND LABORATORY SCIENCE
    21. Park, JW; Smolen, J
      Monoclonal antibody therapy

      ADVANCES IN PROTEIN CHEMISTRY, VOL 56
    22. Morris, CD; Gorlick, R; Huvos, AG; Heller, G; Meyers, PA; Healey, JH
      Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma

      CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
    23. Ritter, G; Cohen, LS; Williams, C; Richards, EC; Old, LJ; Welt, S
      Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33

      CANCER RESEARCH
    24. Molina, MA; Codony-Servat, J; Albanell, J; Rojo, F; Arribas, J; Baselga, J
      Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells

      CANCER RESEARCH
    25. Ryu, DDY; Nam, DH
      Recent progress in biomolecular engineering

      BIOTECHNOLOGY PROGRESS
    26. Gasparini, G; Gion, M
      Molecular-targeted anticancer therapy: Challenges related to study design and choice of proper endpoints

      CANCER JOURNAL
    27. Tsongalis, GJ; Cartun, RW; Ricci, A
      Gene amplification as means for determining therapeutic strategies in human cancers

      CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    28. Adjei, AA
      Signal transduction pathway targets for anticancer drug discovery

      CURRENT PHARMACEUTICAL DESIGN
    29. Park, JW; Tripathy, D; Campbell, MJ; Esserman, LJ
      Biological therapy of breast cancer

      BIODRUGS
    30. Nieto, Y; Champlin, RE; Wingard, JR; Vredenburgh, JJ; Elias, AD; Richardson, PR; Glaspy, J; Jones, RB; Stiff, PJ; Bearman, SI; Cagnoni, PJ; McSweeney, PA; LeMaistre, CF; Pecora, AL; Shpall, EJ
      Status of high-dose chemotherapy for breast cancer: A review

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    31. Treish, I; Schwartz, R; Lindley, C
      Pharmacology and therapeutic use of trastuzumab in breast cancer

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    32. Mendelsohn, J
      Blockade of receptors for growth factors: An anticancer therapy - The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture

      CLINICAL CANCER RESEARCH
    33. Wei, BR; Ghetie, MA; Vitetta, ES
      The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice

      CLINICAL CANCER RESEARCH
    34. Sirotnak, FM; Zakowski, MF; Miller, VA; Scher, HI; Kris, MG
      Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

      CLINICAL CANCER RESEARCH
    35. Sahin, AA
      Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer

      ADVANCES IN ANATOMIC PATHOLOGY
    36. Tsai, SW; Sun, YY; Williams, LE; Raubitschek, AA; Wu, AM; Shively, JE
      Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5

      BIOCONJUGATE CHEMISTRY
    37. Pelegrin, M; Marin, M; Oates, A; Noel, D; Saller, R; Salmons, B; Piechaczyk, M
      Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies

      HUMAN GENE THERAPY
    38. Mendelsohn, J; Baselga, J
      The EGF receptor family as targets for cancer therapy

      ONCOGENE
    39. Turkson, J; Jove, R
      STAT proteins: novel molecular targets for cancer drug discovery

      ONCOGENE
    40. Yu, DH; Hung, MC
      Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

      ONCOGENE
    41. Roh, H; Pippin, JA; Green, DW; Boswell, CB; Hirose, CT; Mokadam, N; Drebin, JA
      HER2/neu antisense targeting of human breast carcinoma

      ONCOGENE
    42. Johnson, RC; Ricci, A; Cartun, RW; Ackroyd, R; Tsongalis, GJ
      p185(HER2) overexpression in human breast cancer using molecular and immunohistochemical methods

      CANCER INVESTIGATION
    43. Baselga, J; Pfister, D; Cooper, MR; Cohen, R; Burtness, B; Bos, M; D'Andrea, G; Seidman, A; Norton, L; Gunnett, K; Falcey, J; Anderson, V; Waksal, H; Mendelsohn, J
      Phase I studies of anti-epidermal growth factor receptor chimeric antibodyC225 alone and in combination with cisplatin

      JOURNAL OF CLINICAL ONCOLOGY
    44. Gilewski, T; Seidman, A; Norton, L; Hudis, C
      An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    45. Green, MC; Murray, JL; Hortobagyi, GN
      Monoclonal antibody therapy for solid tumors

      CANCER TREATMENT REVIEWS
    46. Lane, HA; Beuvink, I; Motoyama, AB; Daly, JM; Neve, RM; Hynes, NE
      ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency

      MOLECULAR AND CELLULAR BIOLOGY
    47. Yu, DH; Hung, MC
      Role of erbB2 in breast cancer chemosensitivity

      BIOESSAYS
    48. Olayioye, MA; Neve, RM; Lane, HA; Hynes, NE
      The ErbB signaling network: receptor heterodimerization in development andcancer

      EMBO JOURNAL
    49. Pegram, M; Slamon, D
      Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy

      SEMINARS IN ONCOLOGY
    50. Ravdin, P
      The use of HER2 testing in the management of breast cancer

      SEMINARS IN ONCOLOGY
    51. Dela Cruz, JS; Trinh, KR; Morrison, SL; Penichet, ML
      Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity

      JOURNAL OF IMMUNOLOGY
    52. Menard, S; Tagliabue, E; Campiglio, M; Pupa, SM
      Role of HER2 gene overexpression in breast carcinoma

      JOURNAL OF CELLULAR PHYSIOLOGY
    53. Yamauchi, T; Yamauchi, N; Ueki, K; Sugiyama, T; Waki, H; Miki, H; Tobe, K; Matsuda, S; Tsushima, T; Yamamoto, T; Fujita, T; Taketani, Y; Fukayama, M; Kimura, S; Yazaki, Y; Nagai, R; Kadowaki, T
      Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer

      JOURNAL OF BIOLOGICAL CHEMISTRY
    54. Sugano, K; Ushiama, M; Fukutomi, T; Tsuda, H; Kitoh, T; Ohkura, H
      Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse

      INTERNATIONAL JOURNAL OF CANCER
    55. Ciardiello, F; Caputo, R; Pomatico, G; De Laurentiis, M; De Placido, S; Bianco, AR; Tortora, G
      Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A

      INTERNATIONAL JOURNAL OF CANCER
    56. Payne, RC; Allard, JW; Anderson-Mauser, L; Humphreys, JD; Tenney, DY; Morris, DL
      Automated assay for HER-2/neu in serum

      CLINICAL CHEMISTRY
    57. Roh, H; Pippin, J; Drebin, JA
      Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu

      CANCER RESEARCH
    58. Clarke, K; Lee, FT; Brechbiel, MW; Smyth, FE; Old, LJ; Scott, AM
      In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice

      CANCER RESEARCH
    59. Dakappagari, NK; Douglas, DB; Triozzi, PL; Stevens, VC; Kaumaya, PTP
      Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine

      CANCER RESEARCH
    60. Scott, AM; Geleick, D; Rubira, M; Clarke, K; Nice, EC; Smyth, FE; Stockert, E; Richards, EC; Carr, FJ; Harris, WJ; Armour, KL; Rood, J; Kypridis, A; Kronina, V; Murphy, R; Lee, FT; Liu, ZQ; Kitamura, K; Ritter, G; Laughton, K; Hoffman, E; Burgess, AW; Old, LJ
      Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors

      CANCER RESEARCH
    61. Pelegrin, A; Xavier, F; Barbet, J; Bartholeyns, J; Baty, D; Buchegger, F; Chatal, JF; Dubief, F; Guerreau, D; Gruaz-Guyon, A; Lamotte, D; Leserman, L; Mach, JP; Robert, B; Saccavini, JC; Teillaud, JL; Teulon, I
      Immunotargeting of tumors: state of the art and prospects in 2000

      BULLETIN DU CANCER
    62. Cornez, N; Piccart, MJ
      Breast cancer and Herceptin

      BULLETIN DU CANCER
    63. Kunisue, H; Kurebayashi, J; Otsuki, T; Tang, CK; Kurosumi, M; Yamamoto, S; Tanaka, K; Doihara, H; Shimizu, N; Sonoo, H
      Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogenon breast cancer cells expressing both oestrogen receptors and HER2

      BRITISH JOURNAL OF CANCER
    64. Jan, AY; Johnson, EF; Diamonti, AJ; Carraway, KL; Anderson, KS
      Insights into the HER-2 receptor tyrosine kinase mechanism and substrate specificity using a transient kinetic analysis

      BIOCHEMISTRY
    65. Visco, V; Bei, R; Moriconi, E; Gianni, W; Kraus, MH; Muraro, R
      ErbB2 immune response in breast cancer patients with soluble receptor ectodomain

      AMERICAN JOURNAL OF PATHOLOGY
    66. Alpaugh, K; von Mehren, M
      Monoclonal antibodies in cancer treatment - A review of recent progress

      BIODRUGS
    67. Perry, CM; Wiseman, LR
      Trastuzumab

      BIODRUGS
    68. Albanell, J; Baselga, J
      The ErbB receptors as targets for breast cancer therapy

      JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
    69. Schrand, LM
      Recent additions to the brewing biotechnology armamentarium: A critical assessment

      FORMULARY
    70. Pegram, M; Hsu, S; Lewis, G; Pietras, R; Beryt, M; Sliwkowski, M; Coombs, D; Baly, D; Kabbinavar, F; Slamon, D
      Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

      ONCOGENE
    71. Mehigan, BJ; Kerin, MJ
      The HER-2/neu story: from oncogene through prognostic marker to therapeutic strategy determinant and monoclonal therapy

      EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
    72. Gorlick, R; Huvos, AG; Heller, G; Aledo, A; Beardsley, GP; Healey, JH; Meyers, PA
      Expression of HER2/erbB-2 correlates with survival in osteosarcoma

      JOURNAL OF CLINICAL ONCOLOGY
    73. Boudny, V; Murakami, Y; Nakano, S; Niho, Y
      Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatinin human gallbladder adenocarcinoma cells

      ANTICANCER RESEARCH
    74. Feldkamp, MM; Lala, P; Lau, N; Roncari, L; Guha, A
      Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens

      NEUROSURGERY
    75. Roh, H; Hirose, CB; Boswell, CB; Pippin, JA; Drebin, JA
      Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents

      SURGERY
    76. Albanell, J; Baselga, J
      Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer

      DRUGS OF TODAY
    77. Ebert, AD; Wechselberger, C; Brandt, R; Martinez-Lacaci, I; Bianco, C; Salomon, DS
      Importance of EGF-related peptides and their receptors in breast cancer

      GEBURTSHILFE UND FRAUENHEILKUNDE
    78. Bieche, I; Onody, P; Laurendeau, I; Olivi, M; Vidaud, D; Lidereau, R; Vidaud, M
      Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications

      CLINICAL CHEMISTRY
    79. Beuzeboc, P; Scholl, S; Garau, XS; Vincent-Salomon, A; de Cremoux, P; Couturier, J; Palangie, T; Pouillard, P
      Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene

      BULLETIN DU CANCER


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/10/20 alle ore 12:27:38